Cullinan Therapeutics Inc CGEM
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if CGEM is a good fit for your portfolio.
News
-
Cullinan Therapeutics to Present Clinical Data from Phase 1 Study Evaluating Novel Anti-MICA/B Antibody, CLN-619, as Monotherapy and in Combination with a Checkpoint Inhibitor in Patients with Advanced Solid Tumors at ASCO 2024
-
Cullinan Therapeutics Announces Strategic Expansion into Autoimmune Diseases
-
Cullinan Therapeutics Announces Oversubscribed $280 million Private Placement
-
Cullinan Oncology Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results
-
Cullinan Oncology Announces U.S. FDA Clearance of Investigational New Drug Application for Novel MICA/B Antibody, CLN-619, for Relapsed/Refractory Multiple Myeloma
-
Cullinan Oncology to Participate in Upcoming Investor Conferences
Trading Information
- Previous Close Price
- $18.89
- Day Range
- $18.23–19.43
- 52-Week Range
- $7.64–20.62
- Bid/Ask
- $10.00 / $19.24
- Market Cap
- $829.01 Mil
- Volume/Avg
- 1.6 Mil / 549,860
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Cullinan Therapeutics Inc is a biopharmaceutical company. It has diversified portfolio of clinical-stage assets that inhibit key drivers of disease or harness the immune system to eliminate diseased cells in both oncology and autoimmune diseases. Its understanding of oncology, immunology, and translational medicine, create differentiated ideas, identify the appropriate targets, and select the optimal modality to develop transformative therapeutics across a variety of cancer and autoimmune indications.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 85
- Website
- https://cullinantherapeutics.com
Comparables
Valuation
|
Metric
|
CGEM
|
ITOS
|
EQRX
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 1.79 | 0.66 | 0.97 |
Price/Sales | — | 30.01 | — |
Price/Cash Flow | — | — | — |
Price/Earnings
CGEM
ITOS
EQRX
Financial Strength
|
Metric
|
CGEM
|
ITOS
|
EQRX
|
|---|---|---|---|
Quick Ratio | 16.60 | 13.46 | 18.43 |
Current Ratio | 17.07 | 13.76 | 18.78 |
Interest Coverage | — | — | — |
Quick Ratio
CGEM
ITOS
EQRX
Profitability
|
Metric
|
CGEM
|
ITOS
|
EQRX
|
|---|---|---|---|
Return on Assets (Normalized) | −24.60% | −12.92% | −15.72% |
Return on Equity (Normalized) | −25.95% | −14.67% | −16.71% |
Return on Invested Capital (Normalized) | −29.67% | −18.54% | −21.31% |
Return on Assets
CGEM
ITOS
EQRX
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Scqfnbpsp | Cnvqr | $562.4 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Wkxzrjqqd | Gyfvf | $103.6 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Ttkdkmbk | Hfrfdd | $99.5 Bil | |
MRNA
| Moderna Inc | Skdnbskd | Gtyz | $38.8 Bil | |
ARGX
| argenx SE ADR | Wdsbnkz | Lwhfz | $22.3 Bil | |
BNTX
| BioNTech SE ADR | Jtrlfwsb | Jprz | $21.2 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Zdykgmyj | Lgqqzzt | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Vdxkwgh | Ljjvvv | $17.3 Bil | |
RPRX
| Royalty Pharma PLC Class A | Nbqxrhqxf | Csygscw | $12.5 Bil | |
INCY
| Incyte Corp | Fhdyjwcl | Tqdpxtv | $11.6 Bil |